Jana Schnaubert (Ulm/ DE), Dr. Peter Reinhardt (Ulm/ DE), Dr. Peter Schauwecker (Ulm/ DE), PD Dr. Daniel Fürst (Ulm/ DE), Dr. Alexandra Ulrich (Ulm/ DE), Dr. Astrid Marx-Hofmann (Ulm/ DE), Daniel Kefalas (Ulm/ DE), Dr. Elisa Sala (Ulm/ DE), Prof. Dr. Ansgar Schulz (Ulm/ DE), Prof. Donald Bunjes (Ulm/ DE), Dr. Markus Wiesneth (Ulm/ DE), Prof. Dr. Hubert Schrezenmeier (Ulm/ DE), Dr. Sixten Körper (Ulm/ DE)
Background
The yield of CD34+ cells obtained by apheresis (HPC-A) crucially depends on the success of CD34+ cell mobilization in combination with the efficiency of CD34+ cell collection. The collection efficiency 2 (CE2) describes the collection process under the assumption of a steady state of CD34+ cell count in peripheral blood throughout the whole procedure. We state the hypothesis that the capacity to maintain the steady state varies between different donors.
Methods
All HPC-A procedures between 27AUG2009 and 14APR2023 were extracted from our electronic records (n=5780, autologous: n=1922, allogeneic: n=3858). HPC-A was performed with the Cobe Spectra or the Spectra Optia. Patients were usually mobilized with G-CSF and chemotherapy. Plerixafor could be used in addition for poor mobilizers. Allogeneic donors were mobilized with G-CSF alone. As the collection efficiency 1 cannot always be calculated from routine data, in addition to CE2 we introduced a process efficiency (PE) calculated by (Number of collected CD34+ cells/ (total blood volume[l] *CD34+ in peripheral blood [cells/l])*100%. Data is given as mean ± S.D.. A Mann-Whitney test was used to test for significance.
Results
CE2 was higher in allogenic than autologous HPC-As (62±34% vs. 58±25%). Using the Spectra Optia the difference was 69±38% (allogenic, n=2727) vs. 58±24% (autologous, n = 1434). Males had higher CE2 in allogeneic (63±38% vs. 60±25%) and autologous HPC-As (60±27% vs. 56±19%). CE2 was slightly higher in multiple myeloma (MM) patients than in other lymphomas (60±20% vs. 57±34). PE was higher in allogeneic than in autologous HPC-As (142±60% vs. 136±70%). There was no difference between MM and lymphoma patients (134±62% vs. 135±81%). For all differences p< 0.001. Linear regressions showed a slight decrease of CE2 on the processed blood volume (PBV) (-2.8%/PBV). PE increased with PBV (58.4%/PBV) or time (0.55%/min).
Conclusion
Different parameters contribute to the success of HPC-A: gender, allogeneic and autologous collection as well as the type of disease influence the effiency of CD34+ cell collection. Multivariate analysis will be provided to better characterize the contributing properties to HPC-A.
Offenlegung Interessenkonflikt:
none
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.